New hope for stubborn lupus? biologic drug trial targets inflammation
NCT ID NCT07381465
Summary
This small, early-stage study is testing a new biologic drug called Firsekibart for people with mild to moderate lupus. It's for patients whose symptoms, like fever, joint pain, or rashes, haven't improved enough with standard medications. The goal is to see if blocking a specific inflammation signal (IL-1) can better control the disease over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.